Decisions loom for water suppliers nationwide after settlements totaling over $11 billion with PFAS manufacturers 3M and DuPont were recently announced.
The pharma landscape is more volatile than ever before, and pushback on drug prices will continue to intensify from payers, PBMs and especially consumers.
It s clear that the push by policymakers to rein in the pharmaceutical industry through regulations that force lower drug prices shows no signs of slowing.
For the past two decades, the biopharma sector has witnessed the shedding of hundreds of thousands of jobs, and all signs point toward an acceleration of these losses.